Insider Trading Alert - FPRX, C And CCF Traded By Insiders

Yesterday, April 21, 2016, 37 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.76 to $2,200,000,000,000.00.

Highlighted Stocks Traded by Insiders:

Five Prime Therapeutics (FPRX) - FREE Research Report

Berger Franklin M, who is Director at Five Prime Therapeutics, bought 6,090 shares at $47.06 on April 21, 2016. Following this transaction, the Director owned 79,980 shares meaning that the stake was boosted by 8.24% with the 6,090-share transaction.

The shares most recently traded at $49.30, up $2.24, or 4.54% since the insider transaction. Historical insider transactions for Five Prime Therapeutics go as follows:

  • 4-Week # shares bought: 25,000
  • 4-Week # shares sold: 1,108
  • 12-Week # shares bought: 25,000
  • 12-Week # shares sold: 1,108
  • 24-Week # shares bought: 25,000
  • 24-Week # shares sold: 1,108

The average volume for Five Prime Therapeutics has been 571,000 shares per day over the past 30 days. Five Prime Therapeutics has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 17.9% year-to-date as of the close of trading on Thursday.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company has a P/E ratio of 5.1. Currently, there are 4 analysts who rate Five Prime Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on FPRX - FREE

TheStreet Quant Ratings rates Five Prime Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Five Prime Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Citigroup (C) - FREE Research Report

Hu W. Bradford, who is Chief Risk Officer at Citigroup, sold 9,528 shares at $45.83 on April 21, 2016. Following this transaction, the Chief Risk Officer owned 53,282 shares meaning that the stake was reduced by 15.17% with the 9,528-share transaction.

The shares most recently traded at $46.97, up $1.14, or 2.43% since the insider transaction. Historical insider transactions for Citigroup go as follows:

  • 4-Week # shares bought: 9,870
  • 4-Week # shares sold: 6,000
  • 12-Week # shares bought: 22,870
  • 12-Week # shares sold: 6,000
  • 24-Week # shares bought: 22,870
  • 24-Week # shares sold: 6,000

The average volume for Citigroup has been 25.7 million shares per day over the past 30 days. Citigroup has a market cap of $132.4 billion and is part of the financial sector and banking industry. Shares are down 9.95% year-to-date as of the close of trading on Thursday.

Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. It operates through two segments, Citicorp and Citi Holdings. The stock currently has a dividend yield of 0.43%. The company has a P/E ratio of 8.6. Currently, there are 12 analysts who rate Citigroup a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on C - FREE

TheStreet Quant Ratings rates Citigroup as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Citigroup Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Chase (CCF) - FREE Research Report

Chadwick Everett JR, who is Director at Chase, sold 90 shares at $57.70 on April 21, 2016. Following this transaction, the Director owned 2,272 shares meaning that the stake was reduced by 3.81% with the 90-share transaction.

The shares most recently traded at $56.75, down $0.95, or 1.67% since the insider transaction. Historical insider transactions for Chase go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 2,250
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 3,900
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 5,400

The average volume for Chase has been 32,600 shares per day over the past 30 days. Chase has a market cap of $521.8 million and is part of the industrial goods sector and industrial industry. Shares are up 39.33% year-to-date as of the close of trading on Wednesday.

Chase Corporation manufactures and sells protective materials for various applications worldwide. It operates through two segments, Industrial Materials and Construction Materials segments. The stock currently has a dividend yield of 1.13%. The company has a P/E ratio of 18.0. Currently, there are no analysts who rate Chase a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCF - FREE

TheStreet Quant Ratings rates Chase as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Chase Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

U.S. Stocks Set For Solid Open as Q3 Earnings Impress; Goldman Boosts Dow

U.S. Stocks Set For Solid Open as Q3 Earnings Impress; Goldman Boosts Dow

Goldman Sachs Profit Jumps as Tax Cuts Fatten the Bottom Line

Goldman Sachs Profit Jumps as Tax Cuts Fatten the Bottom Line

IBM Reports Earnings on Tuesday: 7 Key Things to Watch

IBM Reports Earnings on Tuesday: 7 Key Things to Watch

Netflix, Goldman Sachs, Paul Allen, Google and Ford - 5 Things You Must Know

Netflix, Goldman Sachs, Paul Allen, Google and Ford - 5 Things You Must Know

Walmart Trims 2019 Earnings Guidance After $16 Billion Flipkart Deal

Walmart Trims 2019 Earnings Guidance After $16 Billion Flipkart Deal